BACKGROUND: Cancer patients have an increased risk of thrombosis. Tissue factor (TF) antigen and TF activity associated with microparticles in plasma are elevated in patients with various types of cancer. Of these two measurements, TF activity is considered superior to TF antigen levels because the activity more closely reflects the ability of TF to initiate coagulation. Recent studies showed that platelets also express TF. OBJECTIVE: To determine the level of TF activity associated with a combined platelet and microparticle sample from cancer patients (n = 20) and healthy individuals (n = 23). METHODS: TF activity was measured using a two step chromogenic assay and soluble P-selectin was measured by ELISA in healthy controls and metastatic cancer patients. RESULTS: We determined the composition of a combined platelet and microparticle sample. The sample consisted of platelets, large microparticles (30-200 nm) and membrane debris. We compared the TF activity of a combined platelet and microparticle sample from cancer patients with that from healthy individuals. We found that TF activity in a combined platelet and microparticle sample from cancer patients was higher than in samples from healthy individuals (21.5+/-12.3 pM (n = 20) versus 8.6+/-6.8 pM (n = 23), mean+/-SD, p < 0.001). Cancer patients also had a higher level of soluble P-selectin compared with controls (18.9+/-5.5 ng/mL versus 13.2+/-2.3 ng/mL, p < 0.001). CONCLUSION: This study indicates that measurement of TF activity in a combined platelet and microparticle sample can be used as a simple assay to determine the level of circulating TF.
BACKGROUND:Cancerpatients have an increased risk of thrombosis. Tissue factor (TF) antigen and TF activity associated with microparticles in plasma are elevated in patients with various types of cancer. Of these two measurements, TF activity is considered superior to TF antigen levels because the activity more closely reflects the ability of TF to initiate coagulation. Recent studies showed that platelets also express TF. OBJECTIVE: To determine the level of TF activity associated with a combined platelet and microparticle sample from cancerpatients (n = 20) and healthy individuals (n = 23). METHODS:TF activity was measured using a two step chromogenic assay and soluble P-selectin was measured by ELISA in healthy controls and metastatic cancerpatients. RESULTS: We determined the composition of a combined platelet and microparticle sample. The sample consisted of platelets, large microparticles (30-200 nm) and membrane debris. We compared the TF activity of a combined platelet and microparticle sample from cancerpatients with that from healthy individuals. We found that TF activity in a combined platelet and microparticle sample from cancerpatients was higher than in samples from healthy individuals (21.5+/-12.3 pM (n = 20) versus 8.6+/-6.8 pM (n = 23), mean+/-SD, p < 0.001). Cancerpatients also had a higher level of soluble P-selectin compared with controls (18.9+/-5.5 ng/mL versus 13.2+/-2.3 ng/mL, p < 0.001). CONCLUSION: This study indicates that measurement of TF activity in a combined platelet and microparticle sample can be used as a simple assay to determine the level of circulating TF.
Authors: Michaela Diamant; Rienk Nieuwland; Renée F Pablo; Augueste Sturk; Jan W A Smit; Jasper K Radder Journal: Circulation Date: 2002-11-05 Impact factor: 29.690
Authors: R Nieuwland; R J Berckmans; S McGregor; A N Böing; F P Romijn; R G Westendorp; C E Hack; A Sturk Journal: Blood Date: 2000-02-01 Impact factor: 22.113
Authors: A Zillmann; T Luther; I Müller; M Kotzsch; M Spannagl; T Kauke; U Oelschlägel; S Zahler; B Engelmann Journal: Biochem Biophys Res Commun Date: 2001-02-23 Impact factor: 3.575
Authors: J Himber; C Wohlgensinger; S Roux; L A Damico; J T Fallon; D Kirchhofer; Y Nemerson; M A Riederer Journal: J Thromb Haemost Date: 2003-05 Impact factor: 5.824
Authors: Heather C Inglis; Ali Danesh; Avani Shah; Jacques Lacroix; Philip C Spinella; Philip J Norris Journal: Cytometry A Date: 2015-04-02 Impact factor: 4.355
Authors: Julie A Bastarache; Richard D Fremont; Jonathan A Kropski; Frederick R Bossert; Lorraine B Ware Journal: Am J Physiol Lung Cell Mol Physiol Date: 2009-08-21 Impact factor: 5.464